1. Home
  2. TBPH vs CSIQ Comparison

TBPH vs CSIQ Comparison

Compare TBPH & CSIQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • CSIQ
  • Stock Information
  • Founded
  • TBPH 2013
  • CSIQ 2001
  • Country
  • TBPH United States
  • CSIQ Canada
  • Employees
  • TBPH N/A
  • CSIQ N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • CSIQ Semiconductors
  • Sector
  • TBPH Health Care
  • CSIQ Technology
  • Exchange
  • TBPH Nasdaq
  • CSIQ Nasdaq
  • Market Cap
  • TBPH 699.0M
  • CSIQ 746.1M
  • IPO Year
  • TBPH N/A
  • CSIQ 2006
  • Fundamental
  • Price
  • TBPH $14.40
  • CSIQ $12.01
  • Analyst Decision
  • TBPH Strong Buy
  • CSIQ Hold
  • Analyst Count
  • TBPH 4
  • CSIQ 6
  • Target Price
  • TBPH $23.00
  • CSIQ $11.53
  • AVG Volume (30 Days)
  • TBPH 543.4K
  • CSIQ 2.1M
  • Earning Date
  • TBPH 11-11-2025
  • CSIQ 08-21-2025
  • Dividend Yield
  • TBPH N/A
  • CSIQ N/A
  • EPS Growth
  • TBPH N/A
  • CSIQ N/A
  • EPS
  • TBPH 0.26
  • CSIQ N/A
  • Revenue
  • TBPH $77,205,000.00
  • CSIQ $5,919,361,000.00
  • Revenue This Year
  • TBPH $79.82
  • CSIQ $7.77
  • Revenue Next Year
  • TBPH N/A
  • CSIQ $22.71
  • P/E Ratio
  • TBPH $55.89
  • CSIQ N/A
  • Revenue Growth
  • TBPH 24.49
  • CSIQ N/A
  • 52 Week Low
  • TBPH $7.88
  • CSIQ $6.57
  • 52 Week High
  • TBPH $14.55
  • CSIQ $19.55
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 72.80
  • CSIQ 57.87
  • Support Level
  • TBPH $13.47
  • CSIQ $10.56
  • Resistance Level
  • TBPH $14.42
  • CSIQ $11.25
  • Average True Range (ATR)
  • TBPH 0.41
  • CSIQ 0.67
  • MACD
  • TBPH -0.05
  • CSIQ 0.16
  • Stochastic Oscillator
  • TBPH 86.11
  • CSIQ 95.98

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CSIQ Canadian Solar Inc. (ON)

Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.

Share on Social Networks: